Pharvaris (NASDAQ:PHVS) Stock Price Up 6% – What’s Next?

Pharvaris (NASDAQ:PHVS) rose 6% during trading on Thursday . The company traded as high as $15.80 and last traded at $16.41. Approximately 3,241 shares changed hands during trading, a decline of 95% from the average daily volume of 69,529 shares. The stock had previously closed at $15.48.

Analysts Set New Price Targets

Separately, JMP Securities lifted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Up 1.5 %

The firm has a market capitalization of $826.18 million, a price-to-earnings ratio of -5.64 and a beta of -3.02. The business’s fifty day moving average is $16.73 and its 200 day moving average is $18.93.

Institutional Trading of Pharvaris

Hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc grew its holdings in shares of Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock worth $189,000 after buying an additional 994 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock worth $735,000 after purchasing an additional 1,356 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Pharvaris by 13.0% in the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company’s stock valued at $348,000 after buying an additional 2,087 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after buying an additional 2,847 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in Pharvaris during the third quarter worth $57,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.